Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymalfasin and Entecavir Combination in HBeAg-positive ETV-experienced Patients
NCT03448744Phase 4Unknown
- Start
- Oct 2017
- Primary completion
- Dec 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of thymosin alpha 1 in Chronic Hepatitis B (CHB) (2 arms). Primary endpoint: HBeAg seroconversion rate at 72 weeks. Status: unknown.
02
Drugs
thymosin alpha 1
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03448744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448744.